A study to test how well different doses of BI 3820768 are tolerated by people with advanced cancer (solid tumours)

2025-522913-45-00 · tracked via the Priya Life Science EU tracker

Sponsor

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.

Sponsor type

Pharmaceutical company, Pharmaceutical company

Therapeutic area

Neoplasms

Decision date

20/04/2026

Enrollment target

102

Sites

Spain, France, Belgium, Germany

Condition studied

Advanced relapsed or refractory ovarian cancer, Advanced relapsed or refractory germ cell tumours, Advanced relapsed or refractory endometrial cancer

Eligibility

Age group

18-64 years, 65+ years

Sex

Female, Male

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-522913-45-00 on CTIS ↗ ← All trials in the EU